OBSOLETE: Grix-Blankenship-Peterson syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:2099
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Grix-Blankenship-Peterson syndrome is an extremely rare genetic condition that was first described in the medical literature in the 1980s. This syndrome is now classified as obsolete in some medical databases, meaning it may have been reclassified, merged with another condition, or its original description may have been revised as medical understanding advanced. The condition was originally reported to involve a combination of birth defects affecting multiple body systems, including abnormalities of the growth and development of bones, distinctive facial features, and other congenital malformations. Affected individuals were described as having features such as short stature, limb abnormalities, and craniofacial differences present from birth. Because so few cases have ever been reported in the medical literature, knowledge about this syndrome remains very limited. There is no specific cure or targeted treatment, and management has historically focused on addressing individual symptoms and complications as they arise. Families affected by this condition should work closely with a clinical geneticist to obtain the most current understanding of the diagnosis, as the classification of this syndrome has evolved over time and it may now fall under a different or broader diagnostic category.

Also known as:

Key symptoms:

Short stature or growth delayLimb abnormalitiesUnusual facial featuresBone and skeletal differencesJoint problems or limited joint movementDevelopmental differencesAbnormalities of the hands or feetCraniofacial malformations

Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for OBSOLETE: Grix-Blankenship-Peterson syndrome.

View clinical trials →

No actively recruiting trials found for OBSOLETE: Grix-Blankenship-Peterson syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the OBSOLETE: Grix-Blankenship-Peterson syndrome community →

No specialists are currently listed for OBSOLETE: Grix-Blankenship-Peterson syndrome.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to OBSOLETE: Grix-Blankenship-Peterson syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open OBSOLETE: Grix-Blankenship-Peterson syndromeForum →

No community posts yet. Be the first to share your experience with OBSOLETE: Grix-Blankenship-Peterson syndrome.

Start the conversation →

Latest news about OBSOLETE: Grix-Blankenship-Peterson syndrome

No recent news articles for OBSOLETE: Grix-Blankenship-Peterson syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.Has this diagnosis been reclassified under a different or more current condition name?,Would whole exome or whole genome sequencing help clarify the genetic cause?,What specialists should be part of my child's care team?,Are there any clinical trials or research studies we could participate in?,What developmental milestones should we watch for, and when should we be concerned?,Are there any complications we should monitor for as my child grows?,Can you connect us with other families or support groups for similar conditions?

Common questions about OBSOLETE: Grix-Blankenship-Peterson syndrome

What is OBSOLETE: Grix-Blankenship-Peterson syndrome?

Grix-Blankenship-Peterson syndrome is an extremely rare genetic condition that was first described in the medical literature in the 1980s. This syndrome is now classified as obsolete in some medical databases, meaning it may have been reclassified, merged with another condition, or its original description may have been revised as medical understanding advanced. The condition was originally reported to involve a combination of birth defects affecting multiple body systems, including abnormalities of the growth and development of bones, distinctive facial features, and other congenital malforma

How is OBSOLETE: Grix-Blankenship-Peterson syndrome inherited?

OBSOLETE: Grix-Blankenship-Peterson syndrome follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does OBSOLETE: Grix-Blankenship-Peterson syndrome typically begin?

Typical onset of OBSOLETE: Grix-Blankenship-Peterson syndrome is neonatal. Age of onset can vary across affected individuals.